Waltham, MA and Cambridge, MA 10/1/07—PerkinElmer has agreed to acquire publicly listed ViaCell for $7.25 per share, a 52% premium over the stock’s September 30 closing price, for an aggregated price of approximately $300 million, or $260 million net of cash. ViaCell specializes in the collection and preservation of umbilical cord blood stem cells and, this year, is forecasted to generate revenues in the mid- to high-$60 million range. PerkinElmer expects to divest the company’s therapeutic businesses. “A growing number of disorders—which today includes blood disorders, such as sickle cell anemia, and metabolic disorders—are treatable using the cord blood stem cells gathered and preserved through ViaCell’s ViaCord offering,” stated PerkinElmer President and COO Robert F. Friel. “By bringing both the screening and therapeutic benefits of these two businesses together, we can offer a more comprehensive solution to patients and practitioners.” PerkinElmer forecasts the transaction to be $0.03–0.05 dilutive to adjusted EPS in 2008 and $0.02–$0.03 accretive in 2009. The transaction is expected to close in the fourth quarter.